Last reviewed · How we verify

rosiglitazone-metformin

GlaxoSmithKline · FDA-approved active Small molecule

This combination drug improves insulin sensitivity through a thiazolidinedione (rosiglitazone) that activates PPAR-γ and metformin that reduces hepatic glucose production and improves peripheral insulin sensitivity.

This combination drug improves insulin sensitivity through a thiazolidinedione (rosiglitazone) that activates PPAR-γ and metformin that reduces hepatic glucose production and improves peripheral insulin sensitivity. Used for Type 2 diabetes mellitus.

At a glance

Generic namerosiglitazone-metformin
SponsorGlaxoSmithKline
Drug classThiazolidinedione + Biguanide combination
TargetPPAR-γ (rosiglitazone component); Complex mitochondrial mechanism (metformin component)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Rosiglitazone is a PPAR-γ agonist that enhances insulin sensitivity in muscle and adipose tissue by promoting glucose uptake and reducing insulin resistance. Metformin is a biguanide that decreases hepatic glucose production and improves insulin-mediated glucose uptake in peripheral tissues. Together, they provide complementary mechanisms to lower blood glucose in type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: